Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alterity Therapeutics Limited - American Depositary Shares
(NQ:
ATHE
)
3.830
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
3.830
Bid (Size)
3.650 (1)
Ask (Size)
3.910 (1)
Prev. Close
3.830
Today's Range
3.830 - 3.830
52wk Range
1.001 - 5.870
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alterity Therapeutics Raises A$40.0 million in Placement
February 10, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
February 07, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Performance
YTD
+2.68%
+2.68%
1 Month
-17.10%
-17.10%
3 Month
+68.72%
+68.72%
6 Month
+192.37%
+192.37%
1 Year
+130.72%
+130.72%
More News
Read More
Nasdaq Moves Lower; Meta Platforms Posts Strong Sales
January 30, 2025
Via
Benzinga
What's Going On With Alterity Therapeutics Shares Thursday?
January 30, 2025
Via
Benzinga
Dow Jumps Over 100 Points; Tesla Earnings Miss Views
January 30, 2025
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
January 30, 2025
Via
Stocktwits
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
January 30, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 30, 2025
Via
Benzinga
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
January 30, 2025
Via
Benzinga
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
January 24, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
January 09, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
December 04, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 29, 2024
Via
Benzinga
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
November 19, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
November 12, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
November 06, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
October 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
October 14, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
October 11, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
October 02, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
September 30, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
September 23, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
July 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
July 24, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
